Is Sarilumab included in medical insurance?

Sarilumab (Sarilumab) is a human recombinant monoclonal antibody of the IgG1 subclass. It binds to the IL-6 receptor and has a molecular weight of approximately 150kDa. Salirumab is produced in suspension culture of Chinese hamster ovary cells through recombinant DNA technology. The Salirumab injection for subcutaneous injection is a sterile, colorless to light yellow, preservative-free solution with a pH value of approximately 6.0. Thalirumab is available in a single-dose prefilled syringe or prefilled pen.

Salirumab, a monoclonal antibody directed against the interleukin-6 (IL-6) receptor, has been approved in several countries, including the United States, the European Union, and Japan, as a once-every-2-week subcutaneous regimen for the treatment of moderately to severely active rheumatoid arthritis (RA) who have an inadequate response to or intolerance to one or more DMARDs. Common side effects experienced by patients include neutropenia, thrombocytopenia (low platelet count), upper respiratory and urinary tract infections, oral herpes, hyperlipidemia, and injection site reactions.

The patent drug of Salirutumab is a new type of drug for treating diseases. It has not yet been launched in China, so it is not covered by medical insurance. Patients cannot yet purchase this drug in domestic hospitals or pharmacies. The common dosage form of Salirutumab's original drug is injection, which has been marketed overseas. The price of the European version of the specification200mg*2 per box is around 17,500 (the price may fluctuate due to the exchange rate). There are currently no generic Salirutumab produced in other countries.